EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study

Bogdan Mihai Pascu iD, Irina Bojoga iD, Anca Bălănescu iD, Paul Cristian Bălănescu, Ioan Gherghina

Metabolites · 01.07.2026 · 16 (7) · 460

DOI: 10.3390/metabo16070460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 01.07.2026. Verfasst von Bogdan Mihai Pascu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Department, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 030167 Bucharest, Romania. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: GLP-1 receptor agonists (GLP-1 RAs) are effective weight-loss therapies, but data on body composition changes in pediatric obesity remain scarce. The primary objective was to evaluate the effects of GLP-1 RAs on body composition in children with obesity. Materials and Methods: We conducted a retrospective study of children with obesity evaluated at the National Institute for Mother and Child Health “Alessandrescu-Rusescu”, Bucharest, Romania, who initiated weekly injectable GLP-1 RA therapy (semaglutide) between January and December 2025. Patients were assessed at baseline and after a median follow-up of 5 months. Eight of ten participants with complete paired data were included in the final analysis; two were excluded because one was a non-responder with weight gain and suspected non-compliance, while one responder could not maintain the standing position for bioimpedance measurement. Bioimpedance analysis and anthropometry were performed at both visits. Paired data were analyzed using Wilcoxon signed-rank tests.

Results

Eight children (4 boys, 4 girls; mean age 14.9 ± 1.8 years) completed the study. Significant Body Mass Index (BMI) Z-score improvements were observed (CDC: −0.14, p = 0.012; WHO: −0.37, p = 0.012), with a median weight reduction of 4.75 kg (p = 0.036). While absolute muscle mass showed non-significant change (−1.3 kg, p = 0.362), predicted muscle mass percentage increased significantly (+1.9%, p = 0.012), suggesting selective fat loss. Fat-free mass percentage increased (+2.0%, p = 0.012) with reciprocal fat mass reduction (absolute: −3.85 kg, p = 0.017; percentage: −2.0%, p = 0.012). Fat-free mass index remained stable (−0.67 kg/m2, p = 0.161). No serious adverse events occurred. Sensitivity analysis (n = 10) confirmed the robustness of the results, with improvements in BMI Z-scores remaining significant.

Conclusions

In this preliminary pilot study, GLP-1 RA therapy in children with obesity was associated with significant improvements in BMI Z-scores and favorable shifts in body composition, consistent with selective fat loss and relative preservation of lean mass. These exploratory findings are hypothesis-generating and support the conduct of larger prospective controlled studies with body composition as a primary endpoint.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistbioimpedancebody compositionmuscle preservationpediatric obesity

Autor:innen und Institutionen

  • Pediatric Department, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 030167 Bucharest, Romania.
  • National Institute for Mother and Child Health "Alessandrescu-Rusescu", 020395 Bucharest, Romania.
  • Yuno Clinic, EASO COM Obesity Center, 020459 Bucharest, Romania.
  • Endocrinology and Diabetes Department, "Elias" University Emergency Hospital, 011461 Bucharest, Romania.

ORCID-Profile: Bogdan Mihai Pascu, Irina Bojoga, Anca Bălănescu

Zitieren

APA

Pascu, B. M., Bojoga, I., Bălănescu, A., Bălănescu, P. C., & Gherghina, I. (2026). Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study. Metabolites, 16(7), 460. https://doi.org/10.3390/metabo16070460

Vancouver

Pascu BM, Bojoga I, Bălănescu A, Bălănescu PC, Gherghina I. Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study. Metabolites. 2026;16(7):460. doi:10.3390/metabo16070460

BibTeX
@article{Pascu2026,
  author = {Pascu, Bogdan Mihai and Bojoga, Irina and Bălănescu, Anca and Bălănescu, Paul Cristian and Gherghina, Ioan},
  title = {Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {460},
  doi = {10.3390/metabo16070460}
}
Kostenlos starten →